Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Psychiatry Research and Reviews
  4. Volume 21, Issue 1
  5. Article
Volume 21, Issue 1
  • ISSN: 2666-0822
  • E-ISSN: 2666-0830

Abstract

Introduction

Schizophrenia and schizoaffective disorder are treated in most cases with antipsychotic drugs of the second generation. These drugs block dopaminergic and serotonergic receptors, ., D and 5-HT receptors, and cause different adverse effects, for example, movement disturbances of the extrapyramidal system and adverse effects of vital parameters and of the heart. These drugs treat positive symptoms in schizophrenia and, to a lesser extent, negative symptoms. This review presents the development of newer antipsychotic drugs.

Methods/Material

References were taken from PubMed after using the following keywords: schizophrenia, schizoaffective disorder, antipsychotic drug, neurotransmitter and neuropeptide. Among these newer antipsychotic drugs are cariprazine, brexipiprazole and lumateperone, which exert a partial agonistic effect at D and 5-HT receptors, pimavanserin, a 5-HT receptor antagonist which treats negative symptoms in schizophrenia as an add-on therapy, olanzapine combined with samidorphan, which reduces weight gain, and M or M receptor agonists, for example, xanomeline with an antipsychotic effect combined with trospium, an anticholinergic drug. Neural networks were updated in order to deduce the antipsychotic mechanism of action of newer antipsychotic drugs, especially xanomeline.

Results

The newer antipsychotic drugs cariprazine, brexipiprazole and lumateperone show antipsychotic, antimanic and anti-depressive effects, however, the efficacy on psychotic symptoms in long-term treatment has not yet been examined. Pimavanserin reduces negative symptoms in schizophrenia as an additional pharmacotherapy to treat this disorder. Olanzapine combined with samidorphan exerts good antipsychotic effects and reduces weight gain. The new antipsychotic drug xanomeline, the antipsychotic effect of which is quite different from the antidopaminergic effect, treats positive and negative symptoms in schizophrenia. Its mechanism of action was deduced from the neural networks presented. The long-term efficacy should still be examined.

Conclusion

This review is focused on newer antipsychotic drugs. The long-term efficacy of cariprazine, brexipiprazole and lumateperone in the treatment of schizophrenia should be examined furthermore. Neural networks in the brain areas involved in schizophrenia should be examined and updated furthermore. Newer antipsychotic drugs, for example, xanomeline, an M or M receptor agonist, which has been combined with trospium, an anticholinergic drug, the mechanism of action of which can be derived from the neural network suggested in this review.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cprr/10.2174/0126660822287649240326043815
2025-02-01
2024-11-15

  • From This Site

    /content/journals/cprr/10.2174/0126660822287649240326043815
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WernerF.M. CoveñasR. Classical neurotransmitters and neuropeptides involved in schizoaffective disorder: Focus on prophylactic medication.SharjahBentham Science Publishers201610.2174/97816810821581160101
     [Google Scholar]
  2. WernerF.M. CoveñasR. Safety of antipsychotic drugs: Focus on therapeutic and adverse effects.Expert Opin. Drug Saf.20141381031104210.1517/14740338.2014.935761 24975932
     [Google Scholar]
  3. WernerF.M. CoveñasR. Risk genes in schizophrenia and their importance in choosing the appropriate antipsychotic treatment.Curr. Pharm. Des.202127303281329210.2174/1381612827666210215151333 33588721
     [Google Scholar]
  4. RevueltaG.M. TeránP.J.M. RuizJ.M. Antipsychotic treatment effectiveness in first episode of psychosis: PAFIP 3-year follow-up randomized clinical trials comparing haloperidol, olanzapine, risperidone, aripiprazole, quetiapine, and ziprasidone.Int. J. Neuropsychopharmacol.202023421722910.1093/ijnp/pyaa004 31974576
     [Google Scholar]
  5. PaikJ. Olanzapine/Samidorphan: First approval.Drugs202181121431143610.1007/s40265‑021‑01568‑0 34304374
     [Google Scholar]
  6. PahwaM. SleemA. ElsayedO.H. GoodM.E. El-MallakhR.S. New antipsychotic medications in the last decade.Curr. Psychiatry Rep.202123128710.1007/s11920‑021‑01298‑w 34843030
     [Google Scholar]
  7. CacciaS. InvernizziR.W. NobiliA. PasinaL. A new generation of antipsychotics: Pharmacology and clinical utility of cariprazine in schizophrenia.Ther. Clin. Risk Manag.2013931932810.2147/TCRM.S35137 23966785
     [Google Scholar]
  8. WernerF.M. CoveñasR. New developments in the management of schizophrenia and bipolar disorder: Potential use of cariprazine.Ther. Clin. Risk Manag.20151116571661 26586950
     [Google Scholar]
  9. LaszlovszkyI. BarabássyÁ. NémethG. Cariprazine, a broad-spectrum antipsychotic for the treatment of schizophrenia: Pharmacology, efficacy and safety.Adv. Ther.20213873652367310.1007/s12325‑021‑01797‑5 34091867
     [Google Scholar]
  10. Orzelska-GórkaJ. MikulskaJ. WiszniewskaA. BiałaG. New atypical antipsychotics in the treatment of schizophrenia and depression.Int. J. Mol. Sci.202223181062410.3390/ijms231810624 36142523
     [Google Scholar]
  11. MohrP. MasopustJ. KopečekM. Dopamine receptor partial agonists: Do they differ in their clinical efficacy?Front. Psychiatry20221278194610.3389/fpsyt.2021.781946 35145438
     [Google Scholar]
  12. WuH. SiafisS. HamzaT. Antipsychotic-induced weight gain: Dose-response meta-analysis of randomized controlled trials.Schizophr. Bull.202248364365410.1093/schbul/sbac001 35137229
     [Google Scholar]
  13. de BartolomeisA. CiccarelliM. VellucciL. FornaroM. IasevoliF. BaroneA. Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia.Expert Opin. Pharmacother.202223182035205210.1080/14656566.2022.2145884 36368055
     [Google Scholar]
  14. ThomaS.J. ChalkouK. DörriesC. Comparative efficacy and tolerability of 32 oral and injectable long-acting antipsychotics for the maintenance treatment of adults with schizophrenia: A systematic review and network meta-analysis.Lancet202239982483610.1016/S0140‑6736(21)01997‑8 35219395
     [Google Scholar]
  15. GrossbergG.T. KohegyiE. MergelV. Efficacy and safety of brexipiprazole for the treatment of agitation in Alzheimer’s dementia: Two 12-week, randomized, double-blind, placebo-controlled trials.Am. J. Geriatr. Psychiatry202028438340010.1016/j.jagp.2019.09.009 31708380
     [Google Scholar]
  16. IshigookaJ. IwashitaS. HigashiK. LiewE.L. TadoriY. Pharmacokinetics and safety of brexipiprazole following multiple-dose administration to Japanese patients with schizophrenia.J. Clin. Pharmacol.2018581748010.1002/jcph.979 28750151
     [Google Scholar]
  17. GreigS.L. Brexipiprazole: First global approval.Drugs201575141687169710.1007/s40265‑015‑0462‑2 26310190
     [Google Scholar]
  18. EdinoffA. WuN. deBoisblancC. Lumateperone for the treatment of schizophrenia.Psychopharmacol. Bull.20205043259 33012872
     [Google Scholar]
  19. WernerF.M. CoveñasR. The novel antipsychotic drug cariprazine and cognition enhancing drugs: Indications for their use as the add-on therapy in schizophrenia.Curr. Pharm. Des.202127394033403810.2174/1381612826666201210123229 33302854
     [Google Scholar]
  20. BlairH.A. Lumateperone: First approval.Drugs202080441742310.1007/s40265‑020‑01271‑6 32060882
     [Google Scholar]
  21. SnyderG.L. VanoverK.E. DavisR.E. LiP. FienbergA. MatesS. A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia.In: Advances in Pharmacology. Zorn SH.Elsevier202125327610.1016/bs.apha.2020.09.001
     [Google Scholar]
  22. KirolaB.D. ArangoC. FavaM. Pimavanserin for negative symptoms of schizophrenia: Results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.Lancet Psychiatry202291465810.1016/S2215‑0366(21)00386‑2 34861170
     [Google Scholar]
  23. TsapakisE.M. DiakakiK. MiliarasA. FountoulakisK.N. Novel compounds in the treatment of schizophrenia – A systematic review.Brain Sci.2023138119310.3390/brainsci13081193 37626549
     [Google Scholar]
  24. VietaE. MontesJ.M. A review of asenapine in the treatment of bipolar disorder.Clin. Drug Investig.2018382879910.1007/s40261‑017‑0592‑2 29067671
     [Google Scholar]
  25. CarrithersB. MallakhE.R.S. Transdermal asenapine in schizophrenia: A systematic review.Patient Prefer. Adherence2020141541155110.2147/PPA.S235104 32943849
     [Google Scholar]
  26. CitromeL WallingDP ZeniCM Efficacy and safety of HP-3070, an asenapine transdermal system, in patients with schizophrenia: A phase 3, randomized, placebo-controlled study.J Clin Psychiatry20208220m13602
     [Google Scholar]
  27. MinassianA. YoungJ.W. Evaluation of the clinical efficacy of asenapine in schizophrenia.Expert Opin. Pharmacother.201011122107211510.1517/14656566.2010.506188 20642375
     [Google Scholar]
  28. ChakrabartiA BagnallA ChueP Loxapine for schizophrenia.Cochrane Database Syst Rev20072007CD001943.2310.1002/14651858.CD001943.pub2
     [Google Scholar]
  29. FadenJ. CitromeL. Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.Neuropsychiatr. Dis. Treat.2019152273228310.2147/NDT.S173567 31496709
     [Google Scholar]
  30. DoddS. F CarvalhoA. PuriB.K. Trace amine-associated receptor 1 (TAAR1): A new drug target for psychiatry?Neurosci. Biobehav. Rev.202112053754110.1016/j.neubiorev.2020.09.028 33031817
     [Google Scholar]
  31. DeanB. ScarrE. Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia.Psychiatry Res.202028811298910.1016/j.psychres.2020.112989 32315882
     [Google Scholar]
  32. DeanB. Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal.Expert Opin. Investig. Drugs2023321211131121
     [Google Scholar]
  33. KaulI. SawchakS. CorrellC.U. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.Lancet202440310422160170 38104575
     [Google Scholar]
  34. JonesC.K. ByunN. BubserM. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.Neuropsychopharmacology2012371164210.1038/npp.2011.199 21956443
     [Google Scholar]
  35. YangA. TsaiS.J. New targets for schizophrenia treatment beyond the dopamine hypothesis.Int. J. Mol. Sci.2017188168910.3390/ijms18081689 28771182
     [Google Scholar]
  36. SeemanP. Schizophrenia and dopamine receptors.Eur. Neuropsychopharmacol.2013239999100910.1016/j.euroneuro.2013.06.005 23860356
     [Google Scholar]
  37. StahlS.M. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate.CNS Spectr.201823318719110.1017/S1092852918001013 29954475
     [Google Scholar]
  38. KimS.A. 5-HT1A and 5-HT2A signaling, desensitization, and downregulation: Serotonergic dysfunction and abnormal receptor density in schizophrenia and the prodrome.Cureus2021136e1581110.7759/cureus.15811 34306878
     [Google Scholar]
  39. González-BurgosG. LewisD.A. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia.Schizophr. Bull.200834594496110.1093/schbul/sbn070 18586694
     [Google Scholar]
  40. ShinkaiT. De LucaV. HwangR. Association analyses of the DAOA/G30 and d-amino-acid oxidase genes in schizophrenia: Further evidence for a role in schizophrenia.Neuromolecular Med.20079216917710.1007/BF02685890 17627036
     [Google Scholar]
  41. BallazS.J. BourinM. Cholecystokinin-mediated modulation of anxiety and schizophrenia: A “Dimmer-Switch” hypothesis.Curr. Neuropharmacol.202119792593810.2174/1570159X18666201113145143 33185164
     [Google Scholar]
  42. AlherzF. AlherzM. AlmusawiH. NMDAR hypofunction and somatostatin-expressing GABAergic interneurons and receptors: A newly identified correlation and its effects in schizophrenia.Schizophr. Res. Cogn.201781610.1016/j.scog.2017.02.001 28740825
     [Google Scholar]
  43. LanillosP. OlivaD. PhilippsenA. YamashitaY. NagaiY. ChengG. A review on neural network models of schizophrenia and autism spectrum disorder.Neural Netw.202012233836310.1016/j.neunet.2019.10.014 31760370
     [Google Scholar]
  44. MauriM.C. PalettaS. PaceD.C. Clinical pharmacokinetics of atypical antipsychotics: An update.Clin. Pharmacokinet.20195891219122010.1007/s40262‑019‑00797‑7 31214940
     [Google Scholar]
/content/journals/cprr/10.2174/0126660822287649240326043815
Loading
The Secure Therapeutic Effects of Recently Developed Antipsychotic Drugs and Updated Neural Networks in Schizophrenia
Curr Psyc Res Rev 21, 41 (2025); https://doi.org/10.2174/0126660822287649240326043815
/content/journals/cprr/10.2174/0126660822287649240326043815
/content/journals/cprr/10.2174/0126660822287649240326043815
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Acetylcholine; antipsychotic drug; cariprazine; dopamine; M4 receptor agonist; neural network

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test